Compugen (CGEN) AI Stock Analysis

• Market Cap: $144.04M
• Dividend Yield: N/A
• Average Volume (3M): 261.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: -88.47%
• EPS Growth: -1658.33%
• Country: US
• Employees: 74
• Sector: N/A
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 93,535,355
• 10 Day Avg. Volume: 205,650
• 30 Day Avg. Volume: 261,705
• PEG Ratio: 0.40
• Price to Book (P/B): 2.49
• Price to Sales (P/S): 4.92
• P/FCF Ratio: 2.77
• Enterprise Value/Market Cap: 0.38
• Enterprise Value/Revenue: 7.25
• Enterprise Value/Gross Profit: 8.33
• Enterprise Value/Ebitda: -1.67
• 1Y Price Target: $4.00
• Price Target Upside: 117.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $1.50 ▼(-18.48% Downside)

Compugen's overall stock score is primarily influenced by its financial performance and technical analysis. The company's strategic partnerships and potential future milestones provide some optimism, but current financial challenges and valuation concerns weigh heavily on the score.

Compugen Business Overview & Revenue Model

Company Description

Compugen Ltd. (CGEN) is a biotechnology company focused on discovering and developing therapeutic and diagnostic products for cancer and autoimmune diseases. The company operates primarily in the biopharmaceutical sector, leveraging its proprietary computational discovery platform to identify novel drug candidates and biomarkers. Compugen's core products include monoclonal antibodies and immune checkpoint inhibitors, aimed at enhancing the efficacy of existing therapies and providing new treatment options for patients.

How the Company Makes Money

Compugen generates revenue primarily through collaborations, licensing agreements, and research grants. The company partners with major pharmaceutical companies to co-develop its drug candidates, receiving upfront payments, milestone payments, and royalties on future sales. These partnerships are a key revenue stream, as they provide funding for research and development while sharing the financial risks associated with bringing new therapies to market. Additionally, Compugen may receive funding through government grants aimed at supporting innovative medical research, further contributing to its earnings.

Compugen Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Compugen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEN, the sentiment is Negative. The current price of 1.84 is above the 20-day moving average (MA) of 1.54, above the 50-day MA of 1.63, and above the 200-day MA of 1.55, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.19 is Neutral, neither overbought nor oversold. The STOCH value of 32.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CGEN.

Compugen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
CCCC	56 Neutral	$201.58M	-1.27	-59.98%	―	-10.57%	1.98%
STTK	54 Neutral	$207.56M	-3.28	-57.84%	―	-84.46%	33.32%
CGEN	52 Neutral	$144.04M	-5.15	-52.95%	―	-88.47%	-1658.33%
NVCT	48 Neutral	$197.49M	-5.87	-158.88%	―	―	-16.26%
NKTX	39 Underperform	$128.56M	―	-26.69%	―	―	25.84%
ELTX	30 Underperform	$143.24M	-2.38	―	―	―	17.36%

Compugen Corporate Events

Compugen Reports Q3 2025 Results and Advances Clinical Trials

On November 10, 2025, Compugen Ltd. reported its third quarter 2025 financial results and provided a corporate update. The company highlighted the presentation of COM701 Phase 1 data at ESMO 2025, which informed the design of the ongoing MAIA-ovarian platform trial. Compugen is enrolling patients in the U.S., Israel, and France for this trial, with interim analysis expected in Q1 2027. The company also presented the Phase 1 trial design for GS-0321 at SITC 2025. Partner AstraZeneca shared promising results from Phase 2 trials of rilvegostomig in NSCLC and bladder cancer. Financially, Compugen reported a solid cash position expected to fund operations into Q3 2027, despite a net loss of $6.98 million for the quarter.

Compugen Presents Promising COM701 Analysis at ESMO 2025

On October 13, 2025, Compugen Ltd. announced the presentation of a pooled analysis of COM701 in three Phase 1 trials for patients with platinum-resistant ovarian cancer at the ESMO 2025 conference. The analysis, which included 60 evaluable patients, demonstrated that COM701 was well tolerated and showed durable responses, particularly in patients without liver metastases. This supports the rationale for its use as maintenance therapy in earlier treatment settings. Compugen is currently conducting the MAIA-ovarian trial to assess COM701 as a maintenance treatment in relapsed platinum-sensitive ovarian cancer, with interim analysis results expected by the end of 2026. The company is expanding trial sites to include locations in the U.S., Israel, and France, and anticipates its cash reserves will support operations into 2027.

Compugen’s Shareholders Approve All Proposals at 2025 Annual Meeting

On September 16, 2025, Compugen Ltd. conducted its 2025 Annual General Meeting of Shareholders, where all proposals were approved by the necessary majority vote. This approval signifies continued shareholder support and could potentially strengthen Compugen’s strategic initiatives and market position in the biotechnology sector.